

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Chaoju Eye Care Holdings Limited

朝聚眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2219)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL AND OPERATIONAL HIGHLIGHTS

Revenue of the Group increased by 1.8% to RMB710.7 million for the six months ended June 30, 2026 from RMB698.3 million for the same period in 2025.

Gross profit of the Group decreased by 3.5% to RMB287.2 million for the six months ended June 30, 2026 from RMB297.7 million for the same period in 2025. Gross profit margin decreased to 40.4% for the six months ended June 30, 2026 from 42.6% for the same period in 2025.

Profit before tax of the Group decreased by 17.9% to RMB125.7 million for the six months ended June 30, 2026 from RMB153.1 million for the same period in 2025. Pre-tax profit margin decreased to 17.7% for the six months ended June 30, 2026 from 21.9% for the same period in 2025.

Net profit of the Group decreased by 16.1% to RMB92.9 million for the six months ended June 30, 2026 from RMB110.7 million for the same period in 2025. Net profit margin decreased to 13.1% for the six months ended June 30, 2026 from 15.9% for the same period in 2025.

Non-IFRS adjusted net profit⁽¹⁾ of the Group decreased by 19.3% to RMB95.5 million for the six months ended June 30, 2026 from RMB118.4 million for the same period in 2025. Non-IFRS adjusted net profit margin for the six months ended June 30, 2026 and the six months ended June 30, 2025 were 13.4% and 17.0%, respectively.

Basic earnings per Share of the Group decreased by 12.5% to RMB0.14 for the six months ended June 30, 2026 from RMB0.16 for the same period in 2025.

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

NON-IFRS MEASURES

To supplement the Group's condensed consolidated financial statements which are presented in accordance with IFRS, the Company has provided non-IFRS adjusted net profit⁽¹⁾, non-IFRS adjusted net profit margin, non-IFRS EBITDA and non-IFRS adjusted EBITDA as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. The Company believes that the non-IFRS adjusted financial measures provide useful information to investors and others in understanding and evaluating the Group's condensed consolidated statements of profit or loss in the same manner as they helped the Company's management, and that the Company's management and investors may benefit from referring to these non-IFRS adjusted financial measures in assessing the Group's operating performance from period to period by eliminating impacts of items that the Group does not consider indicative of the Group's operating performance. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS adjusted results on a standalone basis or as a substitute for results under IFRS.

Note:

- (1) Non-IFRS adjusted net profit for the six months ended June 30, 2026 and 2025 was calculated as net profit excluding share-based compensation expenses.

SUMMARY OF UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended June 30, 2026

	Unaudited	
	Six months ended June 30,	
	2026	2025
	(RMB'000)	(RMB'000)
Revenue	710,694	698,258
Cost of sales	(423,458)	(400,591)
Gross profit	287,236	297,667
Other income and gains	24,736	37,833
Selling and distribution expenses	(51,412)	(48,755)
Administrative expenses	(112,593)	(102,167)
Impairment losses on financial assets at amortised cost, net	119	(353)
Other expenses	(17,115)	(25,031)
Finance costs	(5,256)	(6,104)
Share of losses of an associate	(55)	–
Profit before tax	125,660	153,090
Income tax expense	(32,724)	(42,351)
Net profit	92,936	110,739
Non-IFRS adjusted net profit ⁽¹⁾	95,478	118,401
Gross profit margin	40.4%	42.6%
Net profit margin	13.1%	15.9%
Non-IFRS adjusted net profit margin ⁽²⁾	13.4%	17.0%
Non-IFRS EBITDA ⁽³⁾	186,966	210,165
Non-IFRS adjusted EBITDA	189,508	217,827

Notes:

- (1) Adjustments to the net profit for the six months ended June 30, 2026 and 2025 include share-based compensation expenses.
- (2) Non-IFRS adjusted net profit margin was calculated based on non-IFRS adjusted net profit divided by revenue.
- (3) Non-IFRS EBITDA represents profit before tax excluding (i) finance costs; (ii) interest income and fair value gains on financial assets at fair value through profit or loss; (iii) depreciation of property, plant and equipment; (iv) depreciation of investment properties; (v) amortization of intangible assets; and (vi) depreciation of right-of-use assets.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

The Group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. The Group was founded in 1988 in Baotou, Inner Mongolia, as a clinic providing ophthalmic services. Since its inception, the Group adheres to the vision of “Being a Leader of Happy Ophthalmic Healthcare” (成為全球快樂眼健康引領者) and has been “Providing its Patients with a Safe, Reassuring and Pleasant Ophthalmic Medical Experience” with the aid of effective medical equipment and technology as well as professional, caring and considerate services.

As at June 30, 2026, the Group operated a network of 32 ophthalmic hospitals and 32 optical centers spanning across a total of 7 provinces, municipalities and autonomous regions in China. The ophthalmic hospitals specialize in providing ophthalmic services and the optical centers offer a series of optical products and services to satisfy a wide array of requests from customers.

The following table sets forth a breakdown of certain operational information by type of services provided by the Group for the periods indicated:

	Unaudited	
	Six months ended June 30,	
	2026	2025
The hospitals		
Out-patient services		
Number of out-patient visits	554,891	522,051
Average spending per visit (RMB) ⁽²⁾	797	797
In-patient services		
Number of in-patient admissions	34,938	34,844
Average spending per admission (RMB) ⁽²⁾	5,780	6,688
Optical centers		
Number of customer visits ⁽¹⁾	49,982	48,804
Average selling price (RMB) ⁽²⁾	1,052	978

Notes:

- (1) Represents the total number of purchases made by customers at the optical centers. If a customer makes more than one purchase at the optical centers within the same day, he/she will only be counted once. If a customer purchases at the optical centers on different days, he/she will be counted according to the number of days he/she made purchases at the optical centers.
- (2) Subject to rounding adjustments, (i) average spending per visit/admission represents the average spending per visit/admission calculated by the total revenue generated from the out-patient or in-patient services (as applicable) divided by the total number of out-patient or in-patient visit/admission (as applicable); and (ii) average selling price represents the average selling price calculated by the total revenue generated from the optical centers divided by the total number of customer visits.

The Group's revenue increased by 1.8% from RMB698.3 million for the six months ended June 30, 2025 to RMB710.7 million for the six months ended June 30, 2026, primarily due to (1) revenue from medical services remaining basically flat, revenue from consumer ophthalmic services increasing by 3.7% year-on-year, and revenue from basic ophthalmic services decreasing by 4.1% year-on-year. On the one hand, the total number of medical service visits increased year-on-year. Meanwhile, the Company continued to provide patients with more advanced surgical procedures through technology and equipment upgrades, and optimized its revenue structure. Especially the refractive business in consumer ophthalmology, since May 2025, the Company has gradually introduced SMILE-PRO equipment to improve the service pricing system, and achieved a simultaneous increase in both volume and price. On the other hand, for basic ophthalmic services, the settlement unit prices of basic ophthalmic medical insurance all decreased to a certain extent due to the reduction of ophthalmic medical service prices by local medical insurance bureaus in accordance with the Guidelines for the Establishment of Pricing Items for Ophthalmology Medical Services (Trial) since the second half of 2025. (2) the sales revenue from other equipment and consumables increased by RMB12.7 million, mainly due to the Company's continued expansion of its medical supply chain sales business.

The following table sets forth a breakdown of revenue by business segments for the periods indicated:

	Unaudited			
	Six months ended June 30,			
	2026		2025	
	Revenue	Percentage	Revenue	Percentage
	(RMB'000)	of revenue	(RMB'000)	of revenue
Consumer ophthalmic services	372,923	52.5%	359,492	51.5%
Basic ophthalmic services	323,775	45.5%	337,467	48.3%
Sales of equipment and medical consumables	13,996	2.0%	1,299	0.2%
Total	<u>710,694</u>	<u>100.0%</u>	<u>698,258</u>	<u>100.0%</u>

Consumer ophthalmic services

The Group's consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia prevention and control, and provision of optical products and services, the costs for which are currently not covered by public health insurance programs.

To maintain the Group's strong reputation in the provision of consumer ophthalmic services, the Group (i) optimized its marketing and promotion activities with a focus on online promotion, new media and other online channels; (ii) chaired various pro bono eye disease screening activities for the public; (iii) formulated operational management measures to optimize its customer membership management model for maintaining customer loyalty; and (iv) streamlined the admission process to increase the Group's capacity for patient visits.

The Group continued to reinforce the training on consumer ophthalmic services techniques and related skills and improve the service quality in adherence to the Group's core values of "Providing its Patients with a Safe, Reassuring and Pleasant Ophthalmic Medical Experience". Furthermore, the Group also implemented stringent medical quality control measures in providing quality medical services to its patients to enhance its reputation.

In addition, the pricing of consumer ophthalmic services provided by designated hospitals operated by the Group is subject to policy constraints under the Guidelines for the Establishment of Pricing Items for Ophthalmology Medical Services (Trial) with respect to consumer ophthalmology services, while the consumer ophthalmic services provided by other entities operated by the Group are not subject to pricing guidance from public health insurance authorities, whereby the Group retains greater pricing flexibility. The extent of autonomy has enabled the Group to allocate more resources toward driving long-term and sustained growth in consumer ophthalmology services. For the six months ended June 30, 2026, the Group's consumer ophthalmic services contributed to 52.5% of the Group's total revenue. In terms of revenue, consumer ophthalmic services have continued to be the Group's major source of revenue.

Basic ophthalmic services

The Group's basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, the cost of which are partially eligible to be covered by public health insurance programs.

The Group continued to devote significant resources on the procurement of cutting-edge ophthalmic equipment and expand its use of advanced treatment options. This commitment includes the deployment of femtosecond laser-assisted cataract surgery (FLACS) equipment, as well as high-end diagnostic imaging systems and premium consumables. These strategic investments have elevated procedural quality and patient safety, driving stronger satisfaction and higher return rates for our basic ophthalmic services across all our hospitals.

For the six months ended June 30, 2026, the Group's basic ophthalmic services accounted for 45.5% of the Group's total revenue, being another major source of revenue of the Group.

Gross Profit and Gross Profit Margin

The following table sets forth a breakdown of gross profit by business segments and the corresponding gross profit margin for the periods indicated:

	Unaudited			
	Six months ended June 30,			
	2026		2025	
	Gross profit (RMB'000)	Gross Profit margin	Gross profit (RMB'000)	Gross profit margin
Consumer ophthalmic services	158,249	42.4%	150,125	41.8%
Basic ophthalmic services	128,779	39.8%	147,413	43.7%
Sales of equipment and medical consumables	208	1.5%	129	9.9%
Total	<u>287,236</u>	<u>40.4%</u>	<u>297,667</u>	<u>42.6%</u>

The gross profit generated from consumer ophthalmic services was RMB158.2 million for the six months ended June 30, 2026, representing an increase of 5.4% compared to the six months ended June 30, 2025, primarily due to the Company's optimization of the mix of refractive surgical procedures and increased proportion of procedures adopting superior-technology surgical options, which has lifted the overall gross margin of consumer ophthalmic services. The gross profit generated from basic ophthalmic services was RMB128.8 million for the six months ended June 30, 2026, representing a decrease of 12.6% compared to the six months ended June 30, 2025, primarily due to the adjustment of medical insurance prices, but the increase in the number of visits offset the downward pressure on prices to a certain extent, effectively slowing the decline in the overall gross profit. The Group's gross profit was RMB287.2 million for the six months ended June 30, 2026, representing a decrease of 3.5% compared to the six months ended June 30, 2025.

Team of Medical Professionals

The Group has a deep bench of ophthalmic experts with medical expertise and rich experience to treat a wide range of eye diseases and to provide various types of ophthalmic services. The Group focuses on the quality of ophthalmic services and devotes resources to allow its ophthalmologists to provide ophthalmic medical services in a professional, dedicated and responsible manner. The Group is also committed to recruiting and cultivating qualified professionals to form an ophthalmic medical team with outstanding professional and ethical standards and strong sense of responsibility. As of June 30, 2026, the Group had a total of 1,480 full-time medical professionals (June 30, 2025: 1,500), including 323 physicians, 617 nurses and 540 other professionals (June 30, 2025: 320 physicians, 631 nurses and 549 other professionals). Among the 323 physicians, 282 are full-time physicians registered as specialized ophthalmologists. In addition, the Group also had 82 multi-site practice physicians who were full-time employees of other medical institutions.

Awards, Recognitions and Social Responsibility

In 2026, the Group received recognitions and awards at different levels, and was granted the "Distinguished Contribution Award* (突出貢獻大獎)" by the Asian Foundation for the Prevention of Blindness (亞洲防盲基金會). In addition, the Group provides charitable medical aid and medical consultations to public institutions and disadvantaged communities from time to time. Such charitable events allow the Company to maintain good relationships with government authorities and institutions while simultaneously promote its ophthalmic and optical services. These events do not only benefit the disadvantaged communities, but also improve the Group's brand awareness and reputation. For example, in the first half of 2026, the Group:

1. continued to participate in the “Spread the Love in Inner Mongolia, Helping Patients in Pursuit of Health and Dreams” (大愛北疆助康圓夢) charity campaign jointly organized by the Inner Mongolia Disabled Persons’ Federation and Inner Mongolia Disabled Persons’ Welfare Foundation to provide eye examination and treatment services for vulnerable groups;
2. continued to participate in the “Belt and Road: Bright Tour” public welfare project in the China-Mongolia, provided training for optometrists in Mongolia and performed cataract recovery operation services for cataract patients in Mongolia;
3. provided optical screening services to and established medical profiles for primary and secondary school students in Inner Mongolia;
4. provided professional and customized rehabilitation training for children with low vision and squint, and carried out prevention activities to educate children and parents for early diagnosis;
5. conducted various forms of online and offline expert science popularization lectures on eye health for students and their parents for enriching their knowledge in eye health and common eye diseases among children; and
6. led 10 scientific research projects with various authorities and published 8 articles on reputable scientific journals, and published 6 articles domestically.

BUSINESS PROSPECTS AND STRATEGIC HIGHLIGHTS

The demand for ophthalmic medical services has gradually increased in recent years and is expected to remain relatively steady growth rates in the foreseeable future as a result of continued economic growth and an increasingly aging population. However, ophthalmic medical resources in China are scarce, and the penetration rate of surgeries for eye diseases in China is low.

As at the date of this announcement, the Group operated a network of 32 ophthalmic hospitals and 32 optical centers. The Group plans to continue expanding its network layout and strengthening its network coverage in the key regions of North China and expects to acquire more hospitals and optical centers in the coming future. The Group also plans to expand its layout in the key regions of Yangtze River Delta region through acquisitions and establishment of new hospitals and optical centers. As at the date of this announcement, the Group had not entered into any letters of intent or agreements with respect to acquisitions and had not identified any definite acquisition targets.

As a leading ophthalmic medical services group in China, the Group is able to leverage on its branding and market reputation in North China and continue to increase its market share in North China. The Group has further enhanced its brand awareness and reputation in East China through continuously expanding its market share and consolidating the Group's market position in the region. The Group is well-positioned to capture the significant growth potential of the underserved market of private ophthalmic services in China.

Looking into the future and the second half of 2026, the Group expects to:

1. adhere to the vision of “Being a Leader of Happy Ophthalmic Healthcare” to provide effective medical services and continuously revise its improvement plans and promote the “Happy Action” plans;
2. reinforce its leading position in North China and enhance its market positioning in Yangtze River Delta region and other key regions while developing its featured ophthalmic hospitals, new-build and mergers and acquisitions in key regions;
3. seize opportunities in the consumer ophthalmic market and expand consumer ophthalmology by leveraging Chaoju Eye ophthalmic's clinical expertise in ophthalmology diagnosis and treatment in order to become a national chain provider of ophthalmic services trusted by the public;

4. improve the utilization efficiency of its regional resources and strengthen its centralized management model with regional center hospitals as the core;
5. serve with quality medical services and continuously improve patient satisfaction and brand awareness;
6. continue to promote GoLocal Talent Program, actively attract and recruit talents by further refining its training and career developments programs, cultivating its unique corporate culture and offering fair incentives to its key employees;
7. standardize the management of the Group and the communication with regulatory authorities, such as the Stock Exchange, and various professional institutions, so as to improve the comprehensive corporate governance;
8. deepen the application of intelligent technologies and leverage artificial intelligence to enhance our work efficiency; and
9. continue to promote the construction of a sound environmental, social and corporate governance (ESG) system and constantly give back to the society.

Financial Review

Revenue

During the Reporting Period, the Group generated revenue primarily from providing (i) consumer ophthalmic services and (ii) basic ophthalmic services. The revenue of the Group increased by 1.8% from RMB698.3 million for the six months ended June 30, 2025 to RMB710.7 million for the six months ended June 30, 2026.

Consumer ophthalmic services

The Group's consumer ophthalmic services offer a variety of ophthalmic disorder treatments and prevention measures, including myopia control, refractive correction (including presbyopia correction), and provision of optical products and services.

The Group's revenue from consumer ophthalmic services increased by 3.7% from RMB359.5 million for the six months ended June 30, 2025 to RMB372.9 million for the six months ended June 30, 2026, primarily due to the Company's optimization of surgical procedure mix, whereby patients are provided with higher-end surgical techniques, since May 2025, the Company has gradually introduced SMILE-PRO equipment to improve the service pricing system, and achieved a simultaneous increase in both volume and price.

Basic ophthalmic services

The Group's basic ophthalmic services offer a wide range of common eye diseases treatments, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases.

The Group's revenue from basic ophthalmic services decreased by 4.1% from RMB337.5 million for the six months ended June 30, 2025 to RMB323.8 million for the six months ended June 30, 2026, primarily due to tightened national medical insurance charging policy

Cost of Sales

During the Reporting Period, the Group's cost of sales was primarily composed of medical consumables and optical products, employee compensation directly related to the Group's provision of medical services, cost of pharmaceuticals, depreciation, amortization and rental expenses.

The Group's cost of sales increased by 5.7% from RMB400.6 million for the six months ended June 30, 2025 to RMB423.5 million for the six months ended June 30, 2026, primarily due to an increase in sales of pharmaceuticals and consumables.

Gross Profit and Gross Profit Margin

The Group's gross profit decreased by 3.5% from RMB297.7 million for the six months ended June 30, 2025 to RMB287.2 million for the six months ended June 30, 2026.

The Group's gross profit margin decreased from 42.6% for the six months ended June 30, 2025 to 40.4% for the six months ended June 30, 2026. The decrease in gross profit margin was primarily due to adjustments to medical insurance charging policies, which have led to price reductions for multiple medical insurance-covered billing items.

Other Income and Gains

During the Reporting Period, the Group's other income and gains primarily comprised interest income, fair value gains and government grants.

The Group's other income and gains decreased by 34.7% from RMB37.8 million for the six months ended June 30, 2025 to RMB24.7 million for the six months ended June 30, 2026, primarily due to (i) a decrease in governmental subsidies; and (ii) a decrease in interest income.

Selling and Distribution Expenses

During the Reporting Period, the Group's selling and distribution expenses were primarily composed of the compensation of the Group's sales and marketing team, advertising expenses, etc.

The Group's selling and distribution expenses increased by 5.3% from RMB48.8 million for the six months ended June 30, 2025 to RMB51.4 million for the six months ended June 30, 2026, primarily due to the Company's enhanced marketing efforts and targeted deployment of marketing expenses.

Administrative Expenses

During the Reporting Period, the Group's administrative expenses were primarily composed of the compensation of and share-based payments to the Group's administrative and management team, rental expenses, etc.

The Group's administrative expenses increased by 10.2% from RMB102.2 million for the six months ended June 30, 2025 to RMB112.6 million for the six months ended June 30, 2026, primarily due to the Company recruited high-caliber talents to improve its operational performance, resulting in higher payroll expenses.

Other Expenses

During the Reporting Period, the Group's other expenses were primarily composed of impairment losses on non-financial assets and other non-operating expenses. The Group's other expenses decreased by 31.6% from RMB25.0 million for the six months ended June 30, 2025 to RMB17.1 million for the six months ended June 30, 2026. This decrease in other expenses was primarily due to a decrease in impairment of goodwill and intangible assets.

Impairment losses on financial assets at amortised cost, net

During the Reporting Period, the Group's impairment losses on financial assets at amortised cost were primarily composed of provision for impairment losses on trade receivables and other receivables.

The Group's impairment losses on financial assets at amortised cost were RMB0.4 million for the six months ended June 30, 2025 and reversal of impairment loss on financial assets at amortised cost were RMB0.1 million for the six months ended June 30, 2026.

Finance Costs

During the Reporting Period, the Group's finance costs were primarily composed of interest expenses on lease liabilities.

The Group's finance costs were RMB6.1 million for the six months ended June 30, 2025 and RMB5.3 million for the six months ended June 30, 2026.

Income Tax Expense

During the Reporting Period, the income tax rate generally applicable to the Group's subsidiaries in China is 25% and certain subsidiaries of the Group are eligible for a preferential income tax rate of 15%. Certain other subsidiaries are eligible for a preferential income tax rates of 3% or 5% with respect to part of their taxable income.

The Group's income tax expenses decreased by 22.9% from RMB42.4 million for the six months ended June 30, 2025 to RMB32.7 million for the six months ended June 30, 2026, primarily due to a decrease in the profit before tax.

Net Profit and Net Profit Margin

As a result of the foregoing, the Group's net profit decreased by 16.1% to RMB92.9 million for the six months ended June 30, 2026 from RMB110.7 million for the six months ended June 30, 2025. The Group's net profit margin decreased to 13.1% for the six months ended June 30, 2026 from 15.9% for the same period in 2025. The Group defined non-IFRS adjusted net profit as profit for the period adjusted for items which are non-recurring or extraordinary, including share-based compensation expenses. The Group's non-IFRS adjusted net profit decreased by 19.3% to RMB95.5 million for the six months ended June 30, 2026 from RMB118.4 million for the same period in 2025.

Non-IFRS Measures

To supplement the Group's condensed consolidated financial statements which are presented in accordance with IFRS, the Company has provided non-IFRS adjusted net profit, non-IFRS adjusted net profit margin, non-IFRS EBITDA and non-IFRS adjusted EBITDA as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. The Company believes that the non-IFRS adjusted financial measures provide useful information to investors and others in understanding and evaluating the Group's condensed consolidated statements of profit or loss in the same manner as they helped the Company's management, and that the Company's management and investors may benefit from referring to these non-IFRS adjusted financial measures in assessing the Group's operating performance from period to period by eliminating impacts of items that the Group does not consider indicative of the Group's operating performance. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS adjusted results on a stand-alone basis or as a substitute for results under IFRS.

The following table sets forth the reconciliations of the Group's non-IFRS financial measures for the six months ended June 30, 2025 and 2026 to the nearest measures prepared in accordance with IFRS:

	Unaudited	
	Six months ended June 30	
	2026	2025
	(RMB'000)	(RMB'000)
Net Profit	92,936	110,739
Adjustments:		
Share-based compensation expenses	2,542	7,662
Non-IFRS adjusted net profit	95,478	118,401
Non-IFRS adjusted net profit margin	13.4%	17.0%

Note:

Non-IFRS adjusted net profit margin was calculated based on non-IFRS adjusted net profit divided by revenue.

Financial Position

Trade Receivables

The Group's trade receivables decreased by 4.2% from RMB69.4 million as of December 31, 2025 to RMB66.5 million as of June 30, 2026, primarily due to the Company's collection of partial social organisation payments in the first half of 2026 and a slight decrease in medical insurance receivables as a result of the decrease in the Group's basic ophthalmic services.

Cash and Bank Balances

The Group's business operations and expansion plans require significant amount of capital, which will be used for upgrading the existing ophthalmic hospitals and optical centers, establishing and acquiring new hospitals and other working capital requirements. The Group's principal sources of liquidity are cash generated from its business operations, as well as debt and equity financing.

	Unaudited	
	Six months ended June 30,	
	2026	2025
	(RMB'000)	(RMB'000)
Net cash flows from operating activities	174,447	181,554
Net cash flows used in investing activities	(302,299)	(579,217)
Net cash flows used in financing activities	(175,276)	(92,900)
Effect of foreign exchange rate changes, net	3,637	(6,432)
Total decrease in cash and cash equivalents	(299,491)	(496,995)

The Group's total decrease in cash and cash equivalents is RMB299.5 million for the six months ended June 30, 2026, primarily due to net cash inflows of RMB174.4 million from operating activities, and net cash outflows of RMB302.3 million from investing activities, mainly attributable to the purchase of financial products, and net cash outflows of RMB175.3 million from financing activities, which resulted from the payment of dividends for the year ended December 31, 2025.

Trade Payables

The Group's trade payables increased by 43.0% from RMB56.5 million as of December 31, 2025 to RMB80.8 million as of June 30, 2026, primarily due to the increase in visits to refractive and comprehensive eye diseases, which led to higher procurement volumes related to medical consumables and pharmaceuticals, resulting in the increase in payables for medical consumables and pharmaceuticals.

Other Payables and Accruals

The Group's other payables and accruals include salaries and welfare payables, rent payables, equity payables, payables for purchases of property, plant and equipment and contract liabilities.

The Group's other payables and accruals increased by 1.7% from RMB266.9 million as of December 31, 2025 to RMB271.5 million as of June 30, 2026, primarily due to an increase in payables for construction and rent.

Contingent Liabilities

As of June 30, 2026, the Group did not have any material contingent liabilities or guarantees (as at June 30, 2025: nil).

Pledge of Assets

As of June 30, 2026, bank deposits of RMB5.7 million was pledged, which are earmarked for issuing letters of guarantee to ensure the payment of migrant workers' wages in construction projects.

Capital Commitments

As of June 30, 2026, the Group had a total capital commitment of approximately RMB64.6 million (as of December 31, 2025: RMB103.7 million), primarily related to (i) the construction and renovation of its in-network hospitals and the procurement of medical equipment; (ii) the construction of the Chaoju Eye Care Integrated Medical Complex Construction Project Phase I; and (iii) the acquisition of minority shareholders' interests in Hulunbuir Chaoju Eye Hospital Co., Ltd.. The decrease in capital commitments was due to the settlement of previously committed capital contributed to Xiamen Ronghui Hongshang Phase II Equity Investment Partnership (Limited Partnership)* (廈門融匯弘上二期股權投資合夥企業(有限合夥)) during the period.

Significant Investments

The Group subscribed for low-risk short-term wealth management products issued by reputable commercial banks with certain portion of its temporary idle funds (including surplus cash received from its business operations) for treasury management purpose in order to enhance the efficiency, the utilization of and the return on its temporary idle funds. These products are of very low risk nature with satisfactory liquidity and the Group expects that the wealth management products will earn a better yield than current deposits generally offered by commercial banks in the PRC while at the same time offer flexibility to the Group in terms of treasury management. The Group has implemented adequate and appropriate internal control procedures to ensure subscriptions of wealth management products would not affect the working capital or the operations of the Group, and that such investments would be closely monitored and conducted in accordance with the Group's treasury policy. As such, the Board is of the view that the subscriptions of the wealth management products (as listed below) are fair and reasonable and are on normal commercial terms and the subscriptions are in the interests of the Company and the Shareholders as a whole.

As of June 30, 2026, the Group maintained a portfolio of wealth management products with a total outstanding principal amount of RMB561.1 million, representing approximately 18.9% of the Group's total assets.

For the six months ended June 30, 2026, the total principal amount of the wealth management products that the Group has subscribed for was RMB876.1 million and the amount of interest income that the Group has recognized as fair value gains on financial assets at fair value through profit or loss was approximately RMB4.1 million.

The following table sets forth a breakdown of the major wealth management products subscribed by the Group and remain outstanding as at June 30, 2026:

Name of the issuer of the wealth management products	Name of the wealth management products	Deposit starting date	Date of maturity	Principal amount of subscription ⁽¹⁾ (RMB'000)	Expected annualized return rate ⁽²⁾	Realized/Fair	Percentage
						value as of June 30, 2026 (RMB'000)	of the total assets of the Group as of June 30, 2026
JPM	JPM USD Structured Deposit 摩根大通美元結構性存款 (CC59240806000)	June 11, 2026	June 11, 2027	216,068	3.95% +0.10%* N/M ⁽³⁾	216,536	7.28%
BOC	BOC Open-Ended Wealth Management Product 中國銀行開放式理財產品 (Z7001024000691)	April 2, 2026	–	260,000	–	261,168	8.79%
BOC	BOC Open-Ended Wealth Management Product 中國銀行開放式理財產品 (Z7001024000365)	April 29, 2026	–	75,000	–	75,222	2.53%
Hua Xia Bank	Hua Xia Bank Open-Ended Wealth Management Product 華夏銀行開放式理財產品 (Z7003925001635)	December 2, 2025	–	10,000	–	10,183	0.34%

Notes:

- (1) These subscription amounts were all funded by surplus cash of the Group.
- (2) Upon maturity, the Group expects to receive the principal amount together with the expected interest.
- (3) “N” means, in respect of an Interest Period, the number of calendar days during such Interest Period on which the Reference Rate is lower than the Barrier.
- “M” means, in respect of an Interest Period, the actual number of calendar days in such Interest Period.
- “Barrier” means 0.00%

“Reference Rate” means, in respect of any relevant day, the closing rate of the China Bond Government Bond Yield Curve produced by China Central Depository & Clearing Co., Ltd. to reflect the yield-to-maturity of onshore-traded RMB Treasury Coupon Bonds and Treasury Discount Bonds with a maturity of 10 years, expressed as a percentage, which appears on the Bloomberg Screen CNTBI10 <Index> (or any successor or replacement page to such page) as of 6:00 p.m., Beijing time or thereabouts, on such day.

If such rate does not appear, the rate shall be determined by the Calculation Agent in good faith and in a commercially reasonable manner.

Save as disclosed in this announcement, there were no other significant investments held by the Group during the Reporting Period.

Future Plan for Material Investment and Capital Asset

Save as disclosed in this announcement and the Prospectus, up to the date of this announcement, the Group did not have any future plan for material investments and capital assets.

Borrowings and Gearing Ratio

As of June 30, 2026, the Group was in a net cash position and thus, gearing ratio is not applicable.

Foreign Exchange Risk

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect its financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars, has been based on rates set by the People’s Bank of China. The Group seeks to limit its exposure to foreign currency risk by closely monitoring and minimizing its net foreign currency position. During the Reporting Period, the Group did not enter into any currency hedging transactions.

Interest Rate Risk

The Group’s interest rate risk arises from interest-bearing borrowings. Borrowings issued at fixed rates expose the Group to fair value interest rate risk. The Group currently does not use any interest rate swap contracts or other financial instruments to hedge against interest rate exposure.

Credit Risk

Credit risk is the risk regarding the loss arising from a counterparty's inability to meet its obligations. The management of the Group has put in place a credit policy and the exposure to such credit risks is monitored on an on-going basis.

Liquidity Risk

The Group's liquidity is primarily dependent on its ability to maintain adequate cash inflows from operations to meet its debt obligations as they fall due, and the ability to obtain external financing to meet its committed future capital expenditure.

The Group monitors and maintains a level of cash and cash equivalents deemed adequate by its management to finance the operation and mitigate the effects of fluctuations in cash flows.

Interim Dividends

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Since January 1, 2026 and up to the date of this announcement, save as provisions addressed below, the Company has complied with all the applicable code provisions as set out in the Corporate Governance Code (the “**CG Code**”) contained in Appendix C1 to the Listing Rules.

Code provision C.2.1 of the CG Code stipulates that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual.

The roles of chairman of the Board and chief executive officer of the Company are held by Mr. Zhang Bozhou who has extensive experience in the industry. The Board believes that vesting the roles of the chairman and chief executive officer in Mr. Zhang Bozhou is beneficial to the management of the Group and will improve the efficiency of the Group's decision making and executive process given his knowledge in the Group's affairs. Further, the Group has put in place an appropriate check-and-balance mechanism through the Board and the independent non-executive Directors.

In view of the above, the Board considers that such structure will not impair the balance of power and authority between the Board and the management of the Group. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangement when the Board considers appropriate.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix C3 to the Listing Rules as its code of conduct regarding securities transactions by the Directors. Upon specific enquiry, all Directors confirmed that they had complied with the requirements as set out in the Model Code since January 1, 2026 and up to the date of this announcement.

AUDIT COMMITTEE

The Company has established the Audit Committee with written terms of reference in compliance with the requirements under the Listing Rules. The Audit Committee is composed of three independent non-executive Directors, being Mr. Li Jianbin (chairman of the Audit Committee), Ms. Guo Hongyan and Mr. Bao Shan. The primary duties of the Audit Committee are to assist the Board in providing an independent view of the effectiveness of the financial reporting process, the internal control and risk management system of the Group, to oversee the audit process and to perform other duties and responsibilities as assigned by the Board.

PROCEEDS FROM GLOBAL OFFERING AND ITS UTILIZATION

Use of Proceeds from Global Offering

The shares of the Company were listed on the Main Board of the Stock Exchange on July 7, 2021. In the Global Offering, the Company issued 137,500,000 Shares at HK\$10.60 per share and subsequently issued 20,125,000 Shares at HK\$10.60 per share on August 3, 2021 upon partial exercise of the overallotment option. The net proceeds from the Global Offering received by the Company, after deduction of the underwriting fees and commissions and other expenses payable by the Company in connection with the Global Offering, were approximately HK\$1,599 million.

As disclosed in the announcement of the Company dated August 29, 2025 (the “**Announcement**”), the Company intended to use the net proceeds from the Global Offering for the following purposes:

- (i) approximately HK\$800.42 million is intended to be used for the establishment of new hospitals and the relocation, upgrade and renovation of existing hospitals;
- (ii) approximately HK\$548.37 million is intended to be used for acquiring hospitals, when appropriate opportunities arise, in new markets with sizable population and relatively high level of demand for ophthalmic healthcare services;
- (iii) approximately HK\$90.31 million is intended to be used for upgrading information technology systems;
- (iv) approximately HK\$159.90 million is intended to be used for working capital and other general corporate purposes.

The Group had utilized an aggregate of approximately HK\$1,096.49 million of the net proceeds as at June 30, 2026 according to the intentions set out in the Prospectus and the Announcement.

The unutilized net proceeds in the amount of HK\$502.51 million are expected to be utilized as set out on the Prospectus and the Announcement. The following table sets out the planned applications of the net proceeds as well as the expected timeline for utilization:

Use of Proceeds	Revised Allocation of the Net Proceeds from the Global Offering ⁽¹⁾ <i>HK\$ million</i>	Utilized during the six months ended June 30, 2026 <i>HK\$ million</i>	Utilized as at June 30, 2026 <i>HK\$ million</i>	Unutilized as at June 30, 2026 <i>HK\$ million</i>	Updated timeline for utilization ⁽¹⁾⁽²⁾
Establishment of new hospitals and the relocation, upgrade and renovation of existing hospitals	800.42	25.87	491.94	308.48	Expected to be fully utilized on or before December 31, 2027
Acquiring hospitals, when appropriate opportunities arise, in new markets which has sizable population and relatively high level of demand for ophthalmic healthcare services	548.37	0.34	379.94	168.43	Expected to be fully utilized on or before December 31, 2027
Upgrading information technology systems	90.31	4.63	64.71	25.60	Expected to be fully utilized on or before December 31, 2027
Working capital and other general corporate purposes	159.90	–	159.90	–	Fully utilized
Total	1,599.00	30.84	1,096.49	502.51	

Notes:

- (1) The update on the allocation of the net proceeds from the Global Offering and the expected timeline for the use of proceeds as per announcement dated August 29, 2025.
- (2) The updated expected timeline for utilizing the remaining net proceeds is made based on the best estimation of the Company taking into account, among others, the prevailing and future market conditions and business development and need, and is therefore subject to change.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

During the period from January 1, 2026 to June 30, 2026, pursuant to the share repurchase mandate approved by the Shareholders at the annual general meeting of the Company held on June 6, 2025 and May 12, 2026, the Company repurchased 862,000 Shares and 897,000 Shares, respectively, from the Stock Exchange for cancellation. On March 4, 2026, the Company canceled a total of 2,330,000 Shares, which were repurchased by the Company from November 19, 2025 to January 29, 2026. As at June 30, 2026 and the date of this announcement, the Company was holding 1,279,000 Shares and 0 Shares for cancellation, respectively. Details of the repurchases conducted by the Company for the six months ended June 30, 2026 are summarized as follows:

Repurchase date	Price per share		Number of Shares	Total Consideration HK\$
	Highest price HK\$	Lowest price HK\$		
January 6, 2026	2.74	2.68	60,000	162,550
January 8, 2026	2.69	2.66	60,000	160,670
January 13, 2026	2.68	2.64	60,000	159,090
January 15, 2026	2.67	2.63	60,000	158,860
January 20, 2026	2.70	2.64	60,000	160,640
January 22, 2026	2.75	2.69	60,000	163,320
January 27, 2026	2.71	2.69	60,000	161,965
January 29, 2026	2.71	2.68	60,000	162,020
April 2, 2026	2.72	2.72	10,000	27,200
April 9, 2026	2.82	2.82	17,500	49,350
April 14, 2026	2.89	2.79	60,000	168,315
April 23, 2026	2.84	2.74	60,000	167,010
April 28, 2026	2.91	2.87	60,000	173,490
April 30, 2026	2.99	2.87	54,500	161,880
May 5, 2026	3.05	2.99	60,000	181,170
May 7, 2026	3.10	2.91	60,000	176,705
May 12, 2026	2.99	2.96	60,000	178,015
May 14, 2026	2.75	2.66	60,000	162,575
May 19, 2026	2.68	2.65	60,000	160,075
May 21, 2026	2.71	2.64	60,000	159,960
May 26, 2026	2.68	2.62	60,000	158,170
May 28, 2026	2.62	2.54	60,000	154,350
June 2, 2026	2.65	2.58	60,000	156,500
June 4, 2026	2.61	2.56	60,000	154,210
June 9, 2026	2.58	2.52	60,000	152,480
June 11, 2026	2.57	2.51	60,000	152,620
June 16, 2026	2.57	2.55	59,000	151,110
June 18, 2026	2.53	2.51	60,000	150,645
June 23, 2026	2.50	2.47	60,000	148,755
June 25, 2026	2.45	2.41	58,000	140,970
June 30, 2026	2.45	2.40	60,000	145,920

Save as disclosed above, during the period from January 1, 2026 to June 30, 2026, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale and/or transfer of treasury shares).

As at June 30, 2026 and the date of this announcement, the Group did not hold any treasury shares.

EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2026, the Group had 2,619 full-time employees, among which, 1,480 were professionals at the hospitals, 100 were professionals at the optical centers and 1,039 were administrative, finance and other employees at the Group's headquarters, hospitals and optical centers. In addition, the Group also had 82 practice physicians who were fulltime employees of other medical institutions. The following table shows a breakdown of the Group's full-time employees by function as of that date:

	Number of employees	Percentage of total employees
Professionals at the hospitals		
Physicians ⁽¹⁾	323	12.33%
Nurses	617	23.56%
Other professionals	540	20.62%
Professionals at the optical centers	100	3.82%
Administrative, finance and other employees at		
The headquarters	150	5.73%
The hospitals	848	32.38%
The optical centers	41	1.56%
Total	2,619	100.00%

Note:

(1) As of June 30, 2026, 282 of the full-time physicians were registered as specialized ophthalmologists.

The Group enters into employment contracts with all of its full-time employees. The remuneration packages for its employees primarily comprise one or more of the following elements: basic salary, performance-based incentive bonus and discretionary year-end bonus. The Group also sets performance targets for its employees based on their position and regularly reviews their performances, the results of which are used in their annual salary reviews and promotion appraisals.

The Group adopted a share award scheme (the “**Scheme**”) on May 10, 2022, for the purposes of recognizing and motivating the contribution of certain employees of the Group and incentivizing them and helping the Group in retaining its existing employees and attracting and recruiting suitable personnel as additional employees to further the operation and development of the Group and providing them with a direct economic interest in attaining the long-term business objectives of the Group. The Scheme is analogous to a share scheme and subject to provisions of Chapter 17 of the Listing Rules (as amended with effect from January 1, 2023). Further details of the Scheme are set out in the section headed “Share Schemes” in our 2026 interim report to be issued in due course.

The Group provides structured training and education programs which enable its employees to consistently deliver high quality services. The Group’s discipline development committees are responsible for training its medical professionals, maintaining a proper mix of different levels of professionals, as well as research and development, and have supplied numerous young ophthalmologists with solid skills and rich clinical experience. The Group also engages external consultants, experts and professors to provide training for the physicians with an aim to cultivate clinicians with extensive practical capabilities in a precise, standardized and high-quality manner. These programs aim to equip them with a sound foundation of the medical principles, ethics and knowledge as well as practical skills, and foster a high standard of practice. Regular internal and external mandatory online and on-site training are organized for the medical team to keep them abreast of the latest development in the ophthalmology industry. From time to time, the Group identifies and sponsors its employees with high development potential to undertake further study and professional training in prestigious medical institutions. They also support their attending physicians to train at toptier eye hospitals in China for a period of three to six months, such as Wenzhou Medical University Eye Hospital (溫州醫科大學附屬眼視光醫院). In addition, the Group also designs and implements specialized training for its nurses and medical assistants to improve their respective professional skills and foster their professional career path.

As of June 30, 2026, none of the Group’s employees had negotiated with them on the employment terms through the labor unions or in a way of collective bargaining and the Group had not experienced any major labor disputes or labor strikes that had interfered with its operations in any material respect.

REVIEW OF INTERIM RESULTS

The independent auditors of the Company, namely Ernst & Young, have carried out a review of the interim financial information in accordance with the Hong Kong Standard on Review Engagement 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants. The Audit Committee has jointly reviewed with the management and the independent auditors of the Company, the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results for the six months ended June 30, 2026) of the Group. The Audit Committee and the independent auditors considered that the interim results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

EVENTS AFTER THE REPORTING PERIOD

On 10 August 2026, the Company canceled the 3,720,500 Shares which were repurchased by the Company from 2 April 2026 to 28 July 2026.

Save as disclosed above, there is no other significant event that might affect the Group after the Reporting Period.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND THE INTERIM REPORT ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.chaojueye.com), and the 2026 interim report containing all the information required by the Listing Rules will be published on the respective websites of the Stock Exchange and the Company in due course.

The Board is pleased to announce the condensed consolidated interim results of the Group for the six months ended June 30, 2026 together with the comparative figures for the same period in 2025:

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2026

		For the six months ended 30 June	
		2026	2025
	Notes	RMB'000 (Unaudited)	RMB'000 (Unaudited)
REVENUE	4	710,694	698,258
Cost of sales		<u>(423,458)</u>	<u>(400,591)</u>
Gross profit		287,236	297,667
Other income and gains		24,736	37,833
Selling and distribution expenses		(51,412)	(48,755)
Administrative expenses		(112,593)	(102,167)
Impairment losses on financial assets at amortised cost, net		119	(353)
Other expenses		(17,115)	(25,031)
Finance costs		(5,256)	(6,104)
Share of losses of an associate		<u>(55)</u>	<u>–</u>
PROFIT BEFORE TAX	5	125,660	153,090
Income tax expense	6	<u>(32,724)</u>	<u>(42,351)</u>
PROFIT FOR THE PERIOD		<u>92,936</u>	<u>110,739</u>
Attributable to:			
Owners of the parent		94,720	113,643
Non-controlling interests		<u>(1,784)</u>	<u>(2,904)</u>
		<u>92,936</u>	<u>110,739</u>
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	8		
Basic (RMB per share)		<u>0.14</u>	<u>0.16</u>
Diluted (RMB per share)		<u>0.14</u>	<u>0.16</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
PROFIT FOR THE PERIOD	<u>92,936</u>	<u>110,739</u>
OTHER COMPREHENSIVE INCOME		
Exchange differences	<u>(30,274)</u>	<u>(9,704)</u>
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>62,662</u>	<u>101,035</u>
Attributable to:		
Owners of the parent	64,446	103,939
Non-controlling interests	<u>(1,784)</u>	<u>(2,904)</u>
	<u>62,662</u>	<u>101,035</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2026

		30 June 2026 <i>RMB'000</i> (Unaudited)	31 December 2025 <i>RMB'000</i> (Audited)
	<i>Notes</i>		
NON-CURRENT ASSETS			
Property, plant and equipment		610,275	578,599
Investment properties		25,377	26,056
Right-of-use assets		252,094	244,969
Goodwill		136,223	149,670
Intangible assets		142,672	148,142
Investments in an associate		84	139
Financial assets at fair value through profit or loss		159,574	134,018
Deferred tax assets		9,137	6,230
Time deposits		51,291	71,679
Prepayments, other receivables and other assets		16,957	13,299
Pledged deposit		107	5,661
Total non-current assets		1,403,791	1,378,462
CURRENT ASSETS			
Inventories		42,088	42,041
Trade receivables	9	66,466	69,432
Prepayments, other receivables and other assets		62,597	44,954
Financial assets at fair value through profit or loss		563,109	191,354
Pledged deposit		5,594	–
Time deposits		611,937	776,874
Cash and cash equivalents		216,848	516,339
Total current assets		1,568,639	1,640,994
CURRENT LIABILITIES			
Trade payables	10	80,846	56,486
Other payables and accruals		269,567	264,920
Due to related parties		22	22
Interest-bearing other borrowings		2,803	4,455
Lease liabilities		34,693	33,855
Tax payable		16,898	15,868
Total current liabilities		404,829	375,606

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(continued)
30 June 2026

	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
NET CURRENT ASSETS	<u>1,163,810</u>	<u>1,265,388</u>
TOTAL ASSETS LESS CURRENT LIABILITIES	<u>2,567,601</u>	<u>2,643,850</u>
NON-CURRENT LIABILITIES		
Convertible bonds	35,779	35,027
Lease liabilities	174,848	164,301
Deferred tax liabilities	30,317	35,782
Other payables and accruals	<u>1,946</u>	<u>1,938</u>
Total non-current liabilities	<u>242,890</u>	<u>237,048</u>
Net assets	<u><u>2,324,711</u></u>	<u><u>2,406,802</u></u>
EQUITY		
Equity attributable to owners of the parent		
Share capital	151	152
Treasury shares	(27,597)	(49,482)
Equity component of convertible bonds	947	947
Reserves	<u>2,350,531</u>	<u>2,451,694</u>
	<u>2,324,032</u>	<u>2,403,311</u>
Non-controlling interests	<u>679</u>	<u>3,491</u>
Total equity	<u><u>2,324,711</u></u>	<u><u>2,406,802</u></u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2026

		For the six months ended 30 June	
		2026	2025
	Notes	RMB'000	RMB'000
		(Unaudited)	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		125,660	153,090
Adjustments for:			
Finance costs		5,256	6,104
Interest income		(12,887)	(18,462)
Foreign exchange differences, net	5	(5,150)	(2,219)
Fair value gains on financial assets at fair value through profit or loss	5	(3,415)	(4,271)
Depreciation of property, plant and equipment	5	38,820	37,236
Depreciation of investment properties	5	679	679
Depreciation of right-of-use assets	5	25,763	28,579
Amortisation of intangible assets	5	7,090	7,210
Impairment of trade receivables, net	5	1,681	412
Reversal of impairment of other receivables	5	(1,800)	(59)
Impairment of intangible assets	5	–	4,381
Impairment of property, plant and equipment	5	296	–
Write-down of inventories to net realisable value	5	1,738	–
Impairment of goodwill	5	13,447	18,368
Loss/(gain) on disposal of items of property, plant and equipment, net	5	1,026	(79)
Gain on modification of leases	5	–	(1,253)
Gain on termination of leases	5	(83)	–
Share of losses of an associate		55	–
Share-based payments		2,542	7,662
		200,718	237,378
Increase in inventories		(1,785)	(6,785)
Decrease in trade receivables		1,285	3,724
(Increase)/decrease in prepayments, other receivables and other assets		(15,883)	3,282
Increase in trade payables		24,360	10,490
Increase/(decrease) in other payables and accruals		7,659	(18,713)
Increase in pledged deposits		–	(5,607)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (continued)*For the six months ended 30 June 2026*

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Cash generated from operations	216,354	223,769
Interest received	2,646	6,260
Interest paid	(4,487)	(5,224)
Income tax paid	(40,066)	(43,251)
Net cash flows from operating activities	174,447	181,554

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of financial assets at fair value through profit or loss	(906,069)	(200,000)
Proceeds from disposal of financial assets at fair value through profit or loss	512,173	251,812
Placement of time deposits with original maturity over three months	(273,125)	(644,458)
Withdrawal of time deposits with original maturity over three months	439,930	116,650
Purchases of other current financial assets	–	(30,000)
Redemption of other current financial assets	–	40,269
Purchases of items of property, plant and equipment	(73,819)	(112,053)
Purchases of intangible assets	(1,687)	(1,927)
Proceeds from disposal of items of property, plant and equipment	448	490
Payment for investments of an associate	(150)	–
Net cash flows used in investing activities	(302,299)	(579,217)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (continued)

For the six months ended 30 June 2026

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
CASH FLOWS FROM FINANCING ACTIVITIES		
Purchases of shares for share award scheme	(4,152)	(40)
Prepayments received from the award of shares under the share award scheme	–	2,121
Repurchase of restricted shares under the share award scheme	(46)	(419)
Repayment of interest-bearing other borrowings	(1,667)	(527)
Principal portion of lease payments	(21,420)	(16,904)
Dividends paid	(147,991)	(75,981)
Acquisition of non-controlling interests	–	(1,150)
	<u>–</u>	<u>–</u>
Net cash flows used in financing activities	<u>(175,276)</u>	<u>(92,900)</u>
NET DECREASE IN CASH AND CASH EQUIVALENTS	(303,128)	(490,563)
Cash and cash equivalents at beginning of period	516,339	780,785
Effect of foreign exchange rate changes, net	3,637	(6,432)
	<u>3,637</u>	<u>(6,432)</u>
CASH AND CASH EQUIVALENTS AT END OF PERIOD	216,848	283,790
	<u>216,848</u>	<u>283,790</u>
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS		
Cash and bank balances	216,848	283,790
	<u>216,848</u>	<u>283,790</u>
Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows	<u>216,848</u>	<u>283,790</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

30 June 2026

1. CORPORATE INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 19 May 2020. The registered office address of the Company is Level 9, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong.

The Company is an investment holding company. The Company's subsidiaries are involved in the provision of in-patient services, out-patient services, sales of optical products and sales of equipment and medical consumables in the mainland of the People's Republic of China (the "PRC").

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.1 BASIS OF PRESENTATION

The interim condensed consolidated financial information of the Group for the six months ended 30 June 2026 has been prepared in accordance with International Accounting Standard ("IAS") 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period's financial information.

Amendments to IFRS 9 and IFRS 7	<i>Amendments to the Classification and Measurement of Financial Instruments</i>
Amendments to IFRS 9 and IFRS 7	<i>Contracts Referencing Nature-dependent Electricity</i>
<i>Annual Improvements to IFRS Accounting Standards – Volume 11</i>	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

The nature and impact of the amended IFRS Accounting Standards are described below:

- (a) Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.
- (b) Amendments to IFRS 9 and IFRS 7 *Contracts Referencing Nature-dependent Electricity* clarify the application of the "own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.
- (c) Annual Improvements to HKFRS Accounting Standards – Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying Guidance on implementing IFRS 7), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

The Group is principally engaged in the provision of in-patient services, out-patient services, sales of optical products and sales of equipment and medical consumables. For management purposes, the aforesaid businesses are integral and the Group has not organised into different operating segments. Management monitors the results of the Group's operation as a whole for the purpose of making decisions about resource allocation and performance assessment, and accordingly no further operating segment analysis thereof is presented.

Geographical information

As the Group's major operations, customers and non-current assets are located in the People's Republic of China (the "PRC"), no further geographical segment information is provided.

Information about major customers

No revenue from single customers individually accounted for 10% or more of the Group's revenue.

4. REVENUE

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Revenue from contracts with customers	710,694	698,258
Analysed into:		
Consumer ophthalmic services	372,923	359,492
Basic ophthalmic services	323,775	337,467
Sales of equipment and medical consumables	13,996	1,299
Total	710,694	698,258

(a) Disaggregated revenue information for revenue from contracts with customers

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Types of goods or services		
Out-patient services	442,180	416,180
In-patient services	201,923	233,052
Sales of optical products	52,595	47,727
Sales of equipment and medical consumables	13,996	1,299
Total	710,694	698,258

	For the six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Timing of revenue recognition		
Services and goods transferred at a point in time	508,771	465,206
Services transferred over time	201,923	233,052
Total	710,694	698,258

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Depreciation of property, plant and equipment	38,820	37,236
Depreciation of investment properties	679	679
Depreciation of right-of-use assets	25,763	28,579
Amortisation of intangible assets	7,090	7,210
Impairment on trade receivables, net	1,681	412
Reversal of impairment on other receivables	(1,800)	(59)
Write-down of inventories to net realisable value	1,738	–
Impairment of intangible assets [#]	–	4,381
Impairment of items of property, plant and equipment [#]	296	–
Impairment of goodwill [#]	13,447	18,368
Fair value gains on financial assets at fair value through profit or loss	(3,415)	(4,271)
Loss/(gain) on disposal of items of property, plant and equipment, net	1,026	(79)
Gain on modification of leases	–	(1,253)
Gain on termination of leases	(83)	–

[#] Included in other expenses in the interim condensed consolidated statement of profit or loss.

6. INCOME TAX EXPENSE

Pursuant to Caishui [2020] No.23 “Announcement Regarding Continuation of Corporate Tax Policies for the Development of the Western Region” (關於延續西部大開發企業所得稅政策的公告), certain subsidiaries operated in the western region of Chinese mainland are entitled to a preferential corporate income tax rate of 15%, provided that the main business of the subsidiaries belongs to the encouraged projects stipulated in the Catalogue of Encouraged Industries in the Western Region, and such main business income accounts for more than 60% of the total income of the subsidiaries.

Pursuant to Caishui [2022] No.13 “Announcement on Further Implementing the Income Tax Preferential Policies for Small Meagre-profit Enterprises” (關於進一步實施小微企業所得稅優惠政策的公告), from 1 January 2022 to 31 December 2024, certain subsidiaries for the portion of taxable income exceeding RMB1,000,000 but not exceeding RMB3,000,000, the amount of taxable income can be decreased by 75%, and the income tax rate will be levied at 20%.

Pursuant to Caishui [2023] No.6 “Announcement on the Income Tax Preferential Policies for Small Meagre-profit Enterprises and Self-employed Businesses” (關於小微企業和個體工商戶所得稅優惠政策的公告), from 1 January 2023 to 31 December 2024, certain subsidiaries for the portion of taxable income not exceeding RMB1,000,000, the amount of taxable income can be decreased by 75%, and the income tax rate will be levied at 20%.

Pursuant to Caishui [2023] No.12 “Announcement on Relevant Tax and Fee Policies for Further Supporting the Development of Small Meagre-profit Enterprises and Self-employed Businesses” (關於進一步支持小微企業和個體工商戶發展有關稅費政策的公告), the policy of halving the taxable income of small meagre-profit enterprises and self-employed businesses at 25% and levying enterprise income tax at a rate of 20% will be extended until December 31, 2027.

Pursuant to Neishuifa [2024] No.1 “Several Measures by the Taxation Bureau of Inner Mongolia Autonomous Region to Further Support the High-Quality Development of the Private Economy” (內蒙古自治區稅務局進一步支持民營經濟高質量發展的若干措施), effective from 3 January 2024, for small meagre-profit enterprises with an annual taxable income of less than RMB1 million, the local share portion of corporate income tax is exempted.

Under the relevant PRC Corporate Income Tax Law and the respective regulations, except for the preferential treatments available to certain subsidiaries as mentioned above, other subsidiaries within the Group were subject to corporate income tax at the statutory rate of 25%.

Pursuant to the rules and regulations of the Cayman Islands and the British Virgin Islands, the Group is not subject to any income tax in the Cayman Islands and the British Virgin Islands.

No provision for Hong Kong profits tax has been made as the Group had no assessable profits derived from or earned in Hong Kong for the six months ended 30 June 2026 (six months ended 30 June 2025: Nil).

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Current – PRC		
Charge for the period	41,096	47,234
Deferred	(8,372)	(4,883)
Total	32,724	42,351

7. DIVIDENDS

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Final 2025 declared and paid – HK24.23 cents		
(Final 2024: HK11.93 cents) per ordinary share	149,324	77,292
Less: Dividend for shares held under the share award scheme	(1,333)	(1,311)
Total	<u>147,991</u>	<u>75,981</u>

The Board has resolved not to declare any interim dividend for the six months ended June 30, 2026 (six months ended 30 June 2025: Nil).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 694,658,000 (30 June 2025: 691,616,000) outstanding during the period.

The calculation of the diluted earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares.

No adjustment has been made to the basic earnings per share amount in respect of a dilution as the impact of the convertible bonds had no dilutive effect on the basic earnings per share.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent used in the basic and diluted earnings per share calculation	94,720	113,643
Total	<u>94,720</u>	<u>113,643</u>

	Number of shares	
	For the six months ended 30 June	
	2026	2025
	'000	'000
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation	694,658 *	691,616 *
Total	694,658	691,616

* The weighted average number of shares was after taking into account the effect of treasury shares held.

9. TRADE RECEIVABLES

An ageing analysis of the trade receivables at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	30 June	31 December
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Within 3 months	43,770	36,900
4 to 6 months	7,254	11,006
7 to 12 months	7,189	10,474
Over 12 months	8,253	11,052
Total	66,466	69,432

10. TRADE PAYABLES

An ageing analysis of trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June	31 December
	2026	2025
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Within 1 year	73,493	50,085
1 to 2 years	2,608	3,304
2 to 3 years	2,357	1,105
Over 3 years	2,388	1,992
Total	80,846	56,486

GLOSSARY AND DEFINITIONS

“Audit Committee”	the audit committee of the Board
“Board”	the board of Directors
“BOC”	Bank of China Limited
“cataract”	a condition involving the clouding or opacification of the natural lens. Cataract is most commonly caused by aging, but may also be caused by other reasons such as malnutrition, diabetes, trauma or radiation. The opaquer the lens the more the quality of vision is reduced. As a common treatment, clear artificial lenses may be implanted as a substitute for the natural lens to restore clear vision
“China” or the “PRC”	the People’s Republic of China, but for the purpose of this announcement and for geographical reference only, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“Company”	Chaoju Eye Care Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands on May 19, 2020
“Director(s)”	director(s) of the Company
“East China”	an eastern region of China consisting of Hangzhou, Zhoushan and Zhejiang Province
“glaucoma”	an eye condition usually caused by overly high intraocular pressure, which usually causes optic nerve atrophies and visual field defect
“Global Offering”	the Hong Kong Public Offering and the International Offering
“Group”	the Company together with its subsidiaries
“HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC

“IFRS”	the International Financial Reporting Standards
“Inner Mongolia”	the Inner Mongolia Autonomous Region of the PRC, unless the context indicates otherwise
“in-patient services”	treatments of patients who are checked in at hospitals and are hospitalized overnight or for an extended period of time
“IPO Proceeds”	the proceeds obtained by the Company from the Global Offering
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the GEM of the Stock Exchange
“myopia”	a type of refractive error also known as nearsightedness, where the patient is unable to see distant objects clearly. Myopia is usually caused by a longer-than-normal eyeball or excessive refractive ability of the crystalline lens, which results in parallel lights focusing at a position before reaching the retina, thus forming a blurred spot when it reaches the retina
“North China”	a northern region of China consisting of Beijing, Tianjin, Hebei Province, Shanxi Province and Inner Mongolia
“ocular fundus”	the interior surface of the eye opposite the crystalline lens, including the retina, optic disc, macula and posterior pole
“ocular surface”	the interface between the functioning eye and the environment, including the outer layer of the cornea, the conjunctiva, and the margin of the eye lids
“ophthalmologist”	a medical doctor who specializes in eye and vision care
“out-patient services”	treatments of patients who are not checked-in at hospitals and stay at the hospital only for a short period of time (usually completed within the day)

“presbyopia”	an eye condition where the patient has difficulty seeing near items clearly due to declines in refractive abilities of the lens. Presbyopia is a result of the aging of the eye, as the lens loses its natural elasticity and therefore its ability to focus on near objects
“Prospectus”	the prospectus of the Company published on June 24, 2021
“Reporting Period”	the six months ended June 30, 2026
“RMB”	the lawful currency of the PRC
“Scheme”	the share award scheme of the Company as adopted by the Board on May 10, 2022 and as amended from time to time
“Share(s)”	ordinary share(s) in the share capital of the Company with nominal value of HK\$0.00025 each
“Shareholder(s)”	holder(s) of the Shares
“squint”	deviation of the eyes where there is an eye misalignment
“Stock Exchange”	the Stock Exchange of Hong Kong Limited

By order of the Board
Chaoju Eye Care Holdings Limited
ZHANG Bozhou
Chairman

Hong Kong, August 28, 2026

As of the date of this announcement, the board of directors of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. Richard Chen MAO and Mr. LI Zhen as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.

* The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.